These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 7664501

  • 1. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR.
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B, Pettitt D.
    Clin Ther; 1995 Jun; 17(3):572-80. PubMed ID: 7585861
    [No Abstract] [Full Text] [Related]

  • 3. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
    Ginsberg HN.
    Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
    [Abstract] [Full Text] [Related]

  • 4. [In process].
    Reisdorf S.
    Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
    [No Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.
    Black D, Davidson M, Koren M, Bakker-Arkema R, Tresh P, McLain R, Smith D, Hunninghake D.
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):278-85. PubMed ID: 10170452
    [Abstract] [Full Text] [Related]

  • 6. Reducing expenditures for statin-type lipid-lowering agents.
    Am J Health Syst Pharm; 1998 May 15; 55(10):995-6, 999. PubMed ID: 9606450
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE, Phillips JO, Mohiuddin SM, Ryschon KL, Pedersen CA.
    Clin Ther; 1999 Mar 15; 21(3):536-62. PubMed ID: 10321422
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lipid-lowering drugs.
    Med Lett Drugs Ther; 2016 Oct 24; 58(1506):133-140. PubMed ID: 27755510
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fighting high cholesterol levels--lipid lowering drugs.
    Fidge NH.
    Med J Aust; 2016 Oct 24; 159(11-12):815-9. PubMed ID: 8264477
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
    Rackley CE.
    Postgrad Med; 1996 Nov 24; 100(5):61-5, 70-2. PubMed ID: 8917325
    [Abstract] [Full Text] [Related]

  • 17. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Nov 24; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 18. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P.
    Can J Cardiol; 1998 Apr 24; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lipid-lowering drugs: focus on HMG-CoA reductase inhibitors. Introduction.
    Thompson GR.
    Atherosclerosis; 1991 Dec 24; 91 Suppl():S1-2. PubMed ID: 1789811
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.